Phaseline

Companies › Phrontline Biopharma

Phrontline Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TJ101
EGFR/B7H3-directed antibody-drug conjugate with cleavable linker and novel topoisomerase I
EGFR, B7H3Phase 1Lung Cancer (NSCLC)Dec 2026
TJ102
CDH6/FRα directed antibody-drug conjugate with dual payloads
CDH6, FOLR1Phase 1Ovarian CancerSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07181473TJ101Phase 1Lung Cancer (NSCLC)OncologyDec 2026
NCT07778498TJ102Phase 1Ovarian CancerOncologySep 2029

Targets

CDH6 (1) FOLR1 (1) EGFR (1) B7H3 (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Hansoh BioMedical R&D Company Beijing Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Changchun GeneScience Pharmaceutical AbbVie Takeda

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.